Discovery of (2,4-Dihydroxy-5-isopropylphenyl)-[5-(4-methylpiperazin-1-ylmethyl)-1,3-dihydroisoindol-2-yl]methanone (AT13387), a Novel Inhibitor of the Molecular Chaperone Hsp90 by Fragment Based Drug Design
Journal of Medicinal Chemistry2010Vol. 53(16), pp. 5956–5969
Citations Over TimeTop 10% of 2010 papers
Andrew Woodhead, Hayley C. Angove, Maria G. Carr, Gianni Chessari, Miles Congreve, Joseph E. Coyle, José Cosme, Brent Graham, Philip J. Day, Robert Downham, Lynsey Fazal, Ruth E. Feltell, Eva Figueroa, Martyn Frederickson, Jonathan J. Lewis, Rachel McMenamin, Christopher W. Murray, Alistair O’Brien, Lina M. Parra, Sahil Patel, Theresa R. Phillips, David C. Rees, Sharna J. Rich, Donna-Michelle Smith, Gary Trewartha, M. Vinković, Brian Williams, Alison J.‐A. Woolford
Abstract
Inhibitors of the molecular chaperone heat shock protein 90 (Hsp90) are currently generating significant interest in clinical development as potential treatments for cancer. In a preceding publication (DOI: 10.1021/jm100059d ) we describe Astex's approach to screening fragments against Hsp90 and the subsequent optimization of two hits into leads with inhibitory activities in the low nanomolar range. This paper describes the structure guided optimization of the 2,4-dihydroxybenzamide lead molecule 1 and details some of the drug discovery strategies employed in the identification of AT13387 (35), which has progressed through preclinical development and is currently being tested in man.
Related Papers
- → Integration of the accelerator Aha1 in the Hsp90 co-chaperone cycle(2013)127 cited
- → A novel chaperone-activity-reducing mechanism of the 90-kDa molecular chaperone HSP90(1999)77 cited
- → Inhibition of GR‐mediated transcription by p23 requires interaction with Hsp90(2004)46 cited
- → Heat Shock Protein 90 (Hsp90) Chaperone Complex: A Molecular Target for Enhancement of Thermosensitivity and Radiosensitivity.(2002)1 cited
- The Research Advancement of Heat Shock Protein 90 in Tumor Prevention and Therapy(2008)